Sai Life Sciences Limited has released its sixth sustainability report for FY2024-25, demonstrating the company's commitment to responsible growth and environmental stewardship. The report, aligned with Global Reporting Initiative (GRI) Universal Standards 2021 and Sustainability Accounting Standards Board (SASB) standards, is presented under the theme "Driving climate action, deepening stakeholder trust."

Strategic Framework and Sustainability Pillars

The company's sustainability strategy is anchored in nine strategic pillars that collectively guide its approach to responsible growth. These comprehensive elements span multiple areas of operation and stakeholder engagement:

These elements constitute a cohesive framework that embeds sustainability priorities into every stage of the company's operations, aligning with business objectives and stakeholder expectations.

Key Performance Achievements

The report highlights significant progress across multiple sustainability metrics during FY2024-25. The company advanced its internally defined Sustainable Development Goals (SDGs), which outline a clear roadmap for meeting sustainability commitments by March 31, 2027.

Environmental Progress

Social Impact and Community Engagement

Sai Life Sciences demonstrated substantial community impact, surpassing its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities. The organization also strengthened its people agenda with steady growth in diversity initiatives.

Leadership Perspective and Future Outlook

Krishna Kanumuri, MD & CEO of Sai Life Sciences, emphasized the company's commitment to reliability with responsibility as central to the CRDMO mandate. He highlighted the translation of this commitment into action through progress across climate actions, circular economy initiatives, people-led HR transformation, and tech-enabled innovation.

The company is focused on scaling these efforts to build a resilient, science-forward, and sustainability-led operating model that delivers enduring value to partners and stakeholders. The 2024-25 sustainability report reflects the company's long-term view that places science, responsibility, and collaboration at the center of its growth ambition.

Regulatory Compliance and Reporting

The sustainability report release was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This sixth edition continues the company's commitment to transparent reporting and stakeholder communication regarding its sustainability initiatives and progress.

As Sai Life Sciences continues to expand its global footprint with operations across India, the UK, and the US, sustainability remains both a compass and a catalyst for shaping resilient, future-ready operations in the contract research, development, and manufacturing sector.

The report highlights the company's progress in climate action, increased renewable energy usage, and impactful community initiatives, aligning with its commitment to responsible growth and environmental stewardship.

Sai Life Sciences Limited, a prominent player in the pharmaceutical industry, has recently received a tax demand order from the Assistant Commissioner, Central Tax, Division-II (Pimpri), Pune-I Commissionerate. The order, issued under Section 74 of the CGST Act, 2017, calls for the payment of Integrated Goods and Services Tax (IGST) amounting to ₹70.16 lakh, along with applicable interest and an equivalent penalty.

Details of the Tax Demand

The tax authorities have raised concerns over two primary issues:

1. Alleged excess availment of Input Tax Credit (ITC)
2. Discrepancies between B2B supply and the Sale/Purchase register updated on the Government Portal

These issues pertain to the financial years 2018-19 to 2021-22, highlighting the importance of maintaining accurate financial records and compliance with tax regulations.

Company's Response

Sai Life Sciences has stated its intention to file an application for rectification of the order. The company appears confident in its position, expressing that it "does not reasonably expect the order to have any material financial impact on the company." This stance suggests that Sai Life Sciences may have grounds to challenge the tax demand or provide clarifications that could potentially reduce or eliminate the liability.

Financial Implications

While the total demand, including tax and penalty, amounts to ₹1.40 crore, it's important to note that this figure represents less than 0.1% of the company's annual revenue, based on publicly available financial data. The relatively small size of the demand in comparison to the company's overall financial position may explain their optimistic outlook regarding the potential impact.

Upcoming Investor Meetings

In a separate announcement, Sai Life Sciences has rescheduled its participation in the Morgan Stanley Twenty Fourth Annual Asia Pacific Summit. The company will now attend one-on-one meetings in Singapore on November 19 and 20, 2025. This engagement with investors suggests that the company maintains an open line of communication with its stakeholders, even in the face of regulatory challenges.

The company has emphasized that no new presentations will be made during these meetings, and they do not intend to discuss any unpublished price-sensitive information.